News headlines about Xencor (NASDAQ:XNCR) have trended somewhat positive this week, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Xencor earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.486927656941 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
A number of research firms recently commented on XNCR. BidaskClub upgraded shares of Xencor from a “strong sell” rating to a “sell” rating in a report on Thursday, December 7th. Piper Jaffray Companies restated a “buy” rating and set a $35.00 price target on shares of Xencor in a report on Sunday, November 12th. Cantor Fitzgerald started coverage on shares of Xencor in a report on Wednesday, November 29th. They set an “overweight” rating and a $33.00 price target on the stock. Zacks Investment Research restated a “sell” rating on shares of Xencor in a report on Saturday, January 13th. Finally, ValuEngine lowered shares of Xencor from a “hold” rating to a “sell” rating in a report on Monday, October 23rd. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. Xencor has a consensus rating of “Hold” and a consensus target price of $30.80.
Shares of Xencor (XNCR) opened at $21.56 on Friday. Xencor has a 1-year low of $18.55 and a 1-year high of $28.64. The stock has a market cap of $1,012.48, a P/E ratio of -21.56 and a beta of 2.09.
Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.04). Xencor had a negative net margin of 148.29% and a negative return on equity of 15.26%. equities research analysts forecast that Xencor will post -1.1 earnings per share for the current fiscal year.
In related news, major shareholder John S. Stafford III acquired 24,653 shares of the stock in a transaction that occurred on Wednesday, October 25th. The shares were purchased at an average cost of $20.01 per share, with a total value of $493,306.53. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder John S. Stafford III acquired 50,000 shares of the stock in a transaction that occurred on Thursday, November 2nd. The shares were bought at an average cost of $19.58 per share, for a total transaction of $979,000.00. The disclosure for this purchase can be found here. Insiders have bought 278,535 shares of company stock worth $5,526,936 in the last 90 days. 4.03% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Xencor (XNCR) Earns Daily News Sentiment Score of 0.17” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/21/xencor-xncr-earns-daily-news-sentiment-score-of-0-17.html.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.